These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25498525)

  • 1. IFN-β and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks.
    Severa M; Rizzo F; Giacomini E; Salvetti M; Coccia EM
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):229-39. PubMed ID: 25498525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
    Marckmann S; Wiesemann E; Hilse R; Trebst C; Stangel M; Windhagen A
    Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFN-β differentially regulates the function of T cell subsets in MS and EAE.
    Kavrochorianou N; Markogiannaki M; Haralambous S
    Cytokine Growth Factor Rev; 2016 Aug; 30():47-54. PubMed ID: 27033173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocyte subpopulations, oxidative burst and apoptosis in peripheral blood cells of patients with multiple sclerosis-effect of interferon-beta.
    Mix E; Stefan K; Höppner J; Klauer T; Zettl UK; Strauss U; Meyer-Rienecker HJ; Rolfs A
    Autoimmunity; 2003 Aug; 36(5):291-305. PubMed ID: 14567559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
    Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
    Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-beta inhibits Th1 responses at the dendritic cell level. Relevance to multiple sclerosis.
    Bartholomé EJ; Willems F; Crusiaux A; Thielemans K; Schandené L; Goldman M
    Acta Neurol Belg; 1999 Mar; 99(1):44-52. PubMed ID: 10218092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory effects of IFN-beta and lovastatin on immunophenotype of monocyte-derived dendritic cells in multiple sclerosis.
    Bartosik-Psujek H; Tabarkiewicz J; Pocinska K; Radej S; Stelmasiak Z; Rolinski J
    Arch Immunol Ther Exp (Warsz); 2010 Aug; 58(4):313-9. PubMed ID: 20526818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory effects of interferon-β on osteopontin and interleukin-17 expression in multiple sclerosis.
    Hong J; Hutton GJ
    J Interferon Cytokine Res; 2010 Oct; 30(10):751-7. PubMed ID: 20874252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation.
    Gigli G; Caielli S; Cutuli D; Falcone M
    Immunology; 2007 Nov; 122(3):409-17. PubMed ID: 17617156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
    Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.
    Sellebjerg F; Krakauer M; Limborg S; Hesse D; Lund H; Langkilde A; Søndergaard HB; Sørensen PS
    PLoS One; 2012; 7(6):e35927. PubMed ID: 22701554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-beta therapy for multiple sclerosis--is the injection site the relevant action site?
    Smith D
    J Neuroimmunol; 2009 Oct; 215(1-2):117-21. PubMed ID: 19773087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis.
    Rizzo F; Giacomini E; Mechelli R; Buscarinu MC; Salvetti M; Severa M; Coccia EM
    Immunol Cell Biol; 2016 Oct; 94(9):886-894. PubMed ID: 27265253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent progress in treatment for multiple sclerosis].
    Kira J
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1261-3. PubMed ID: 11464473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
    Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
    Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.
    Hemmer B; Stüve O; Kieseier B; Schellekens H; Hartung HP
    Lancet Neurol; 2005 Jul; 4(7):403-12. PubMed ID: 15963443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interferon beta treatment in multiple sclerosis].
    Ochi H
    Nihon Rinsho; 2003 Aug; 61(8):1367-73. PubMed ID: 12962025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.